|
Richard S. Isaacson, M.D.
Preventive Neurologist
Institute for Neurodegenerative Diseases
University of Florida
Richard S. Isaacson, MD is a Preventive Neurologist who conducts clinical and translational research at the Institute for Neurodegenerative Diseases, Florida. He founded and directed the first Alzheimer’s Prevention Clinic in the United States in 2013 at Weill Cornell Medicine/NewYork-Presbyterian. He previously served as Assistant Dean of Faculty Development and Associate Professor of Neurology at Weill Cornell Medicine & NewYork-Presbyterian, and Director of the Center for Brain Health and Director of the Alzheimer’s Prevention Clinic (APC) at Florida Atlantic University’s Schmidt College of Medicine. Prior to that, he served as Associate Professor of Clinical Neurology, Vice Chair of Education, and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. He completed his residency in Neurology at Beth Israel Deaconess Medical Center/Harvard Medical School, and his medical internship at Mount Sinai Medical Center in Miami Beach, FL. Prior to UM, he served as Associate Medical Director of the Wien Center for Alzheimer’s disease and Memory Disorders at Mount Sinai.
A graduate of the accelerated 6-year B.A./M.D. program at the University of Missouri - Kansas City School of Medicine, Dr. Isaacson specializes in AD risk reduction in patients with no cognitive complaints and a family history of the disease, and pre-clinical AD. His clinical research has shown that individualized clinical management of patients at risk for AD dementia may be an important strategy for optimizing cognitive function and reducing dementia risk. He has published novel methods on using a precision medicine approach in real-world clinical practice of AD risk reduction. He served as PI for the APC Comparative Effectiveness Dementia & Alzheimer’s study, has served as PI and/or Co-I on a myriad of grants related to AD prevention, treatment and education, and has ongoing work using whole genome sequencing to assess polygenic risk and refine care.
Dr. Isaacson previously served as Neurology Residency (12 years) and Clerkship Director (5 years), and his career in education spans undergraduate (student), graduate (resident/fellow), and continuing (faculty) medical education, as well as patient, caregiver and community education/outreach. He led the development of Alzheimer’s Universe, a vast online education research portal on AD (>2.5 million unique visitors since 2014) with results published broadly. He served as Chair of the American Academy of Neurology (AAN) e-Learning Subcommittee where he has led a video education interview series in collaboration with Neurology Today on Covid-19, and helped to launch the bimonthly “NeuroBytes” online video-based education program. He also directed a multi-institution e-Learning collaboration on Faculty Development, led several online education research projects (including a CME-course on AD risk reduction via AlzU.org/CME, and brain health courses in partnership with comedic actor Seth Rogen for high school, college, and medical students via AlzU.org/HFCU, which was published in Neurology), chaired the AAN Undergraduate Education Subcommittee working group in dementia, and received the AAN Education Research Grant for “Evaluating the effectiveness of Continuum: Dementia as a teaching tool for medical students” also published in Neurology. He believes that through effective medical communication strategies, harnessing the broad reach of online, print and broadcast media can be an exceptional tool to disseminate information in Neurology and Medicine. He has been quoted in hundreds of news stories and featured by major television (ABC, CBS, NBC, CNN, FOX, etc) and print (WSJ, NY Times, AARP, Discover, O, Readers Digest, etc) outlets, including cover stories on the 2016 US News & World Report Best Hospitals Edition, Psychology Today, and others, totaling over 300 million impressions. With a broad background in computer science, m-Health, biotechnology and web-development, Dr. Isaacson is committed to using technology and comprehensive physical and cognitive assessments to optimize patient care, AD risk assessment and early intervention. Leading distinct, yet interwoven clinical research and technology teams, he is currently leading an NIH-funded clinical trial of a digital therapeutic for AD risk reduction to begin in Q3 2023. In the past, he has studied digital biomarkers using a wearable biosensor and remains committed to rigorously evaluating the effects of personalized, evidence-based multi-modal interventions on cognition, serum/radiologic biomarkers of AD and calculated AD and cardiovascular risk. Considering his family history, including his Uncle Bob (diagnosed with AD while he was in high school) and his Dad’s Cousin (diagnosed over ten years ago), he passionately believes in a comprehensive approach toward both AD treatment and prevention. Dr. Isaacson is the author of numerous publications, his research in neurology and medical education has been presented at scientific meetings nationally and internationally, and was awarded the 2009 AAN A.B. Baker Teacher Recognition Award. He is also a member of the Alpha Omega Alpha Medical Honor Society.
Join In person in the Marshall A. Wolf Conference Center, Hale Building, 3rd floor or via Zoom https://partners.zoom.us/j/5823462701
*Note lunch will be served for in person attendees
Steps to claim CME credits for BWH Neurology Grand Rounds:
Send code COFSAV to 1-857-214-2277.
For more information about BWH Neurology Grand Rounds 2022-2023 click here
If you have any questions about the CME credit, please contact Partners Office of Continuing Professional Development at PartnersCPD@partners.org.
The MGB CPD Team welcomes your feedback on their CME process. Please email Tracy Young-Pearse, Ph.D. and William R. Renthal, M.D., Ph.D. with your comments.
Recordings of past seminars
| 
